STOCK TITAN

Ascendis Pharma - ASND STOCK NEWS

Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.

Overview

Ascendis Pharma (ASND) is a biopharmaceutical company headquartered in Copenhagen, Denmark, that leverages its innovative TransCon technology platform to develop new therapies aimed at addressing significant unmet medical needs. Recognized for its work in rare endocrine diseases, oncology, and growth disorders, the company has established itself as a comprehensive drug development organization integrating research, clinical development, and commercialization across a global footprint.

TransCon Technology Platform

The core of Ascendis Pharma's innovation lies in its TransCon technology platform. This proprietary system is strategically designed to create prodrugs that allow for sustained and controlled release of active pharmaceutical ingredients. The platform is pivotal for the development of therapies that require continuous physiological exposure, enhancing the efficacy and safety profiles of interventions for diseases such as hypoparathyroidism and growth hormone deficiencies.

Product Pipeline and Core Therapeutic Areas

Ascendis Pharma's product portfolio is both diverse and robust. Its pipeline primarily focuses on:

  • Endocrinology: Developing groundbreaking treatments such as TransCon PTH, a prodrug of parathyroid hormone (PTH [1-34]), aimed at providing sustained exposure in the management of hypoparathyroidism. The company's work in this area addresses the challenges associated with conventional calcium and vitamin D therapies.
  • Oncology: Although the company is widely recognized for its endocrine therapies, its research extends into oncology where novel therapeutic approaches are in development.
  • Growth Disorders: With programs like TransCon hGH, the company is innovating in the treatment of growth hormone deficiencies in both pediatric and adult populations. The emphasis on reducing dosing frequency and improving patient compliance is a significant aspect of its strategy.
  • Skeletal Dysplasias: Ascendis is also advancing therapies for conditions such as achondroplasia with candidates like TransCon CNP, which aim to improve growth outcomes in affected children.

This diverse pipeline is a testament to the company’s expertise in transforming biological mechanisms into effective therapeutic solutions, all while adhering to rigorous standards of safety and efficacy.

Global Presence and Strategic Collaborations

Operating across North America, Europe, and other regions, Ascendis Pharma has cultivated a strong international presence. Its global operations facilitate wide-reaching clinical trials and regulatory engagements, ensuring that its therapies have the potential to address patient needs on a worldwide scale.

Additionally, the company has established important strategic collaborations with other industry leaders. These partnerships not only enhance its research and development capabilities but also enable the sharing of expertise and resources. Such collaborations are critical in the biopharmaceutical landscape, where the integration of diverse scientific insights and commercial strategies drives innovation and market success.

Innovation, Scientific Rigor, and Patient-Centric Approach

At its core, Ascendis Pharma is guided by the principles of Patients, Science, and Passion. The company is dedicated to advancing the science behind its therapies while maintaining a clear focus on improving patient outcomes. Its research strategy involves not only pioneering new therapeutic approaches but also optimizing existing treatments through refined dosing regimens, innovative drug delivery systems, and a deep understanding of disease mechanisms.

This patient-centric approach is supported by robust clinical development programs, which have generated pivotal data across multiple therapeutic areas. The emphasis on sustainability and improved patient quality of life is reflected in the company's continued efforts to offer treatments that are both effective and convenient.

Operational Excellence and Business Model

Ascendis Pharma’s business model is built on rapid, successful drug development that integrates discovery research with clinical and commercial operations. The company invests substantially in R&D to drive the translation of scientific innovation into market-ready therapies. By applying its TransCon platform across various product categories, the company demonstrates a commitment to operational excellence and the efficient use of resources.

Its strategic investments in technology, infrastructure, and cross-functional expertise underscore a model that is both agile and scalable, enabling Ascendis Pharma to navigate the complex regulatory landscapes and capitalize on market opportunities as they arise.

Future-Ready Corporate Culture

Although the content here is designed to be evergreen, it captures Ascendis Pharma’s ongoing mission to not only innovate but also to remain resilient and adaptive in a rapidly evolving industry. With a strong foundation in scientific research, a commitment to operational integration, and a global reach, the company is well-positioned to continue delivering solutions that make a meaningful difference in patient lives.

Conclusion

In summary, Ascendis Pharma stands out in the biopharmaceutical industry through its dedicated application of TransCon technology, its expansive and diverse product pipeline, and its deep-rooted commitment to patient care. The company’s approach of integrating innovative scientific research with extensive global operations provides a comprehensive understanding of how cutting-edge therapies can transform healthcare outcomes. Investors and researchers alike can appreciate the detailed strategy behind Ascendis Pharma’s continued efforts to address rare and challenging health conditions, thereby establishing its significance in today’s competitive market landscape.

Rhea-AI Summary

Ascendis Pharma (NASDAQ: ASND) announced FDA acceptance of its supplemental Biologics License Application (sBLA) for TransCon hGH to treat adult growth hormone deficiency (GHD), with a PDUFA date set for July 27, 2025. The application is supported by the foresiGHt Phase 3 trial, which evaluated 259 adults with GHD aged 23-80 years.

The trial demonstrated TransCon hGH's superiority in primary and key secondary efficacy endpoints at Week 38, showing significant reduction in trunk fat and increased total body lean mass compared to placebo. The treatment was generally safe and well-tolerated, with no discontinuations related to study drug and comparable safety to daily hGH treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
-
Rhea-AI Summary

Ascendis Pharma reported Q3 2024 financial results with total revenue of €57.8 million, including SKYTROFA revenue of €47.2 million and YORVIPATH ex-U.S. revenue of €8.5 million. The company plans U.S. YORVIPATH launch with product availability in mid-January 2025. TransCon CNP NDA submission for achondroplasia is planned for Q1 2025. A new collaboration with Novo Nordisk was announced for metabolic and cardiovascular diseases. Full-year 2024 SKYTROFA revenue guidance is €200-220 million, with operating expenses projected at €600 million. Cash position stands at €626 million as of September 30, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
-
Rhea-AI Summary

Ascendis Pharma (Nasdaq: ASND) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast or register for the teleconference through provided links. A replay will be available on the company's investor relations website for 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
Rhea-AI Summary

Ascendis Pharma (ASND) has entered into a licensing agreement with Novo Nordisk for the exclusive worldwide rights to its TransCon technology platform. The collaboration focuses on developing products for metabolic and cardiovascular diseases, with a lead program targeting a once-monthly GLP-1 receptor agonist for obesity and type 2 diabetes. Ascendis will receive up to $285 million in upfront, development, and regulatory milestone payments for the lead program, plus sales-based milestones and tiered royalties. Additional product candidates could earn up to $77.5 million each in milestone payments plus royalties. Ascendis will handle early development while Novo Nordisk will manage clinical development, regulatory affairs, manufacturing, and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) presented 3-year results from their ongoing Phase 2 PaTH Forward Trial at ASBMR 2024. The study, involving 57 adults with hypoparathyroidism, showed that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 normalized bone remodeling.

Hypoparathyroidism is associated with low bone remodeling rates, accumulation of overly mature bone, and higher-than-average bone mineral density, potentially indicating poorer overall bone quality. The results suggest that long-term palopegteriparatide treatment promotes skeletal health parameters similar to those in parathyroid sufficiency.

TransCon PTH is a once-daily prodrug of parathyroid hormone (PTH [1-34]), designed to provide continuous PTH exposure over 24 hours. Dr. Mishaela Rubin, Associate Professor of Medicine at Columbia University, presented the findings in an oral presentation titled 'Palopegteriparatide Improves Skeletal Dynamics in Adults with Chronic Hypoparathyroidism: 3 Year Results from the Phase 2 PaTH Forward Trial' (#1091).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) has submitted a supplemental Biologics License Application (sBLA) to the FDA for TransCon hGH to treat adults with growth hormone deficiency (GHD). This submission aims to expand the label of SKYTROFA®, currently approved for pediatric GHD in the U.S. The sBLA is based on results from the foresiGHt Phase 3 trial, which compared weekly TransCon hGH with weekly placebo and daily hGH in 259 adults with GHD aged 23-80.

The trial demonstrated that TransCon hGH was superior to placebo in reducing trunk fat and increasing total body lean mass at Week 38. It was generally safe and well-tolerated, with no discontinuations related to the study drug and comparable safety to daily hGH. This submission supports Ascendis Pharma's strategy to develop SKYTROFA into a blockbuster product and address the unmet medical need in adult GHD treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its public offering of 2,000,000 American Depositary Shares (ADSs) at $150.00 per ADS. The offering is expected to close around September 23, 2024. Ascendis has also granted underwriters a 30-day option to purchase up to 300,000 additional ADSs. The company estimates net proceeds of approximately $281.3 million, which will be used for commercial preparations, launch activities, clinical development, regulatory approvals, and general corporate purposes.

J.P. Morgan, Morgan Stanley, Evercore ISI, and Goldman Sachs & Co. are acting as joint book-running managers. BofA Securities, Wells Fargo Securities, and Citigroup are lead managers, while Oppenheimer & Co. is co-manager for the offering. A shelf registration statement has been filed with the SEC, and the offering is being made through a prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) has announced a proposed public offering of $300 million in American Depositary Shares (ADSs). Each ADS represents one ordinary share of Ascendis. The company plans to grant underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the public offering price, less underwriting commissions.

The offering is subject to market conditions, with no assurance of completion or final terms. J.P. Morgan, Morgan Stanley, Evercore ISI, and Goldman Sachs & Co. are acting as joint book-running managers. A shelf registration statement has been filed with the SEC, and the offering will be made through a prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
-
Rhea-AI Summary

Ascendis Pharma announced positive topline data from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) for children with achondroplasia. The trial met its primary objective, demonstrating superior annualized growth velocity (AGV) compared to placebo:

- Overall AGV difference: 1.49 cm/year (p<0.0001)
- Ages 5-11: 1.78 cm/year difference (p<0.0001)
- Ages 2-<5: 1.02 cm/year difference (p=0.0084)

TransCon CNP also showed improvements in height Z-scores and quality of life measures. The treatment was generally well-tolerated with a safety profile comparable to placebo. Ascendis plans to submit an NDA to the FDA in Q1 2025 and an MAA to the EMA in Q3 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.07%
Tags
none
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) has announced initial data from its Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ in platinum-resistant ovarian cancer (PROC) patients. The study showed anti-tumor clinical responses in 29% (4/14) of efficacy-evaluable patients treated with TransCon IL-2 β/γ in combination with chemotherapy. These results suggest clinical activity in heavily pre-treated PROC patients, including those who had previously progressed on Elahere®. The treatment was generally well-tolerated, with most treatment-emergent adverse events being grade 1 or 2. The data will be presented at ESMO 2024 in Barcelona. This follows promising results in melanoma announced at ASCO 2024, indicating potential efficacy across multiple cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
conferences earnings clinical trial

FAQ

What is the current stock price of Ascendis Pharma (ASND)?

The current stock price of Ascendis Pharma (ASND) is $142.67 as of April 4, 2025.

What is the market cap of Ascendis Pharma (ASND)?

The market cap of Ascendis Pharma (ASND) is approximately 8.7B.

What is Ascendis Pharma's core business focus?

Ascendis Pharma is a biopharmaceutical company focused on developing innovative therapies using its proprietary TransCon technology platform. Its primary areas include endocrine rare diseases, oncology, and growth disorders.

How does the TransCon technology platform work?

The TransCon technology platform is designed to create prodrugs that provide sustained, controlled release of active molecules. This allows for continuous exposure of the therapeutic agent and potentially improves both efficacy and safety profiles.

Which therapeutic areas are covered by Ascendis Pharma's pipeline?

The company’s pipeline encompasses several key areas, including endocrinology (such as treatments for hypoparathyroidism), oncology, growth hormone deficiencies, and skeletal dysplasias like achondroplasia.

What markets does Ascendis Pharma operate in?

Ascendis Pharma operates globally with a significant presence in North America, Europe, and other international regions. This global operational footprint supports its clinical development and regulatory strategies worldwide.

How does Ascendis Pharma ensure patient-centric development?

The company focuses on a patient-centric approach by addressing unmet medical needs, optimizing dosing regimens, and designing therapies that enhance patient compliance and quality of life. Clinical trials are structured to rigorously evaluate safety and efficacy.

What strategic collaborations support Ascendis Pharma's business model?

Ascendis Pharma actively collaborates with global industry leaders to enhance its research, development, and commercialization capabilities. These partnerships help integrate diverse expertise and resources across the drug development lifecycle.
Ascendis Pharma

Nasdaq:ASND

ASND Rankings

ASND Stock Data

8.73B
60.08M
0.78%
110.41%
6.65%
Biotechnology
Healthcare
Link
Denmark
Hellerup